{"analyses":[{"ciLowerLimit":"0.37","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.95","groupDescription":"Stratified by 3 factors: previous rituximab treatment, time since last antilymphoma therapy (≤ 2, \\> 2 years), and disease histology (FL, MZL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.59"}],"classes":[{"categories":[{"measurements":[{"comment":"insufficient number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received rituximab 375 mg/m\\^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but \\< 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.","id":"OG000","title":"Rituximab + Lenalidomide (R^2)"},{"description":"Participants received rituximab 375 mg/m\\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up to 12 cycles.","id":"OG001","title":"Rituximab + Placebo"}],"paramType":"MEDIAN","populationDescription":"The ITT population is defined as all participants who were randomized into the trial, regardless of whether they received study treatment or not.","reportingStatus":"POSTED","timeFrame":"From date of randomization to death due to any cause (Average of 55.71 months and a maximum up to 95.2 months)","title":"Kaplan-Meier Estimate of Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}